Latest Insider Transactions at Tactile Systems Technology Inc (TCMD)
This section provides a real-time view of insider transactions for Tactile Systems Technology Inc (TCMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TACTILE SYSTEMS TECHNOLOGY INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TACTILE SYSTEMS TECHNOLOGY INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 08
2023
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+25.78%
|
-
|
|
May 08
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
550
-1.83%
|
$9,900
$18.55 P/Share
|
|
May 08
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
786
-2.1%
|
$14,148
$18.65 P/Share
|
|
Mar 01
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,391
-2.77%
|
$19,474
$14.1 P/Share
|
|
Feb 28
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
251
-0.5%
|
$3,514
$14.58 P/Share
|
|
Feb 28
2023
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
700
-0.55%
|
$9,800
$14.56 P/Share
|
|
Feb 28
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
72
-0.24%
|
$1,008
$14.54 P/Share
|
|
Feb 28
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
135
-0.36%
|
$1,890
$14.58 P/Share
|
|
Feb 27
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,801
-7.01%
|
$57,015
$15.36 P/Share
|
|
Feb 27
2023
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
6,387
-4.77%
|
$95,805
$15.27 P/Share
|
|
Feb 27
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
1,401
-4.44%
|
$21,015
$15.33 P/Share
|
|
Feb 27
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,162
-5.45%
|
$32,430
$15.39 P/Share
|
|
Feb 25
2023
|
Brent Moen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,304
+4.08%
|
-
|
|
Feb 25
2023
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,482
+4.62%
|
-
|
|
Feb 25
2023
|
Eric Pauls Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
595
+1.85%
|
-
|
|
Feb 25
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
962
+2.37%
|
-
|
|
Feb 22
2023
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,613
+29.24%
|
-
|
|
Feb 22
2023
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,414
+50.0%
|
-
|
|
Feb 22
2023
|
Eric Pauls Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
12,627
+28.99%
|
-
|
|
Feb 22
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
16,724
+30.18%
|
-
|
|
Aug 08
2022
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
1,020
-1.35%
|
$9,180
$9.18 P/Share
|
|
Aug 04
2022
|
William W Burke Director |
BUY
Open market or private purchase
|
Direct |
4,900
+16.7%
|
$44,100
$9.15 P/Share
|
|
May 19
2022
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
1,100
-5.33%
|
$11,000
$10.12 P/Share
|
|
May 09
2022
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+35.45%
|
-
|
|
May 09
2022
|
Deepti Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+43.93%
|
-
|
|
May 09
2022
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+43.93%
|
-
|
|
May 09
2022
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+36.97%
|
-
|
|
May 09
2022
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+45.43%
|
-
|
|
May 09
2022
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,103
+45.43%
|
-
|
|
May 06
2022
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
600
-3.17%
|
$7,800
$13.03 P/Share
|
|
May 06
2022
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
999
-4.35%
|
$12,987
$13.04 P/Share
|
|
Mar 07
2022
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
176
-0.34%
|
$3,520
$20.64 P/Share
|
|
Mar 01
2022
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,632
-3.04%
|
$32,640
$20.33 P/Share
|
|
Feb 28
2022
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
624
-1.15%
|
$11,856
$19.84 P/Share
|
|
Feb 28
2022
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
877
-1.14%
|
$16,663
$19.78 P/Share
|
|
Feb 24
2022
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,435
+50.0%
|
-
|
|
Feb 24
2022
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,435
+50.0%
|
-
|
|
Feb 24
2022
|
Eric Pauls Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
12,944
+40.65%
|
-
|
|
Feb 24
2022
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
16,181
+41.34%
|
-
|
|
Feb 24
2022
|
Brent Moen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,126
+34.9%
|
-
|
|
Feb 24
2022
|
Daniel L. Reuvers Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,937
+41.32%
|
-
|
|
Oct 01
2021
|
Kevin H Roche Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,755
+12.69%
|
$257,550
$10.79 P/Share
|
|
Sep 02
2021
|
Brent Moen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
486
-1.89%
|
$21,384
$44.87 P/Share
|
|
Aug 06
2021
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
1,063
-4.48%
|
$45,709
$43.11 P/Share
|
|
Jul 07
2021
|
Daniel L. Reuvers Director |
SELL
Open market or private sale
|
Direct |
2,961
-11.09%
|
$145,089
$49.75 P/Share
|
|
Jun 24
2021
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
6,761
-44.21%
|
$371,855
$55.0 P/Share
|
|
Jun 24
2021
|
William W Burke Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,761
+19.84%
|
$116,415
$15.84 P/Share
|
|
May 17
2021
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+20.04%
|
-
|
|
May 17
2021
|
Deepti Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+42.67%
|
-
|
|
May 17
2021
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+42.67%
|
-
|